Mandate

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm

February 27, 2014

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm and Nordic Capital Fund V:s offering of shares in connection with the listing. Bufab is a trading company that delivers components and services to the global manufacturing industry. Bufab is a trading company that delivers components and services to the global manufacturing industry. The Company offers its customers a one-stop-shop product offering that covers sourcing, quality assurance and logistics of so called C-Parts, components such as nuts, screws and washers, according to the business model Supply Chain Partner. The Swedish language prospectus was published on 10 February 2014 and the first day of trading was 21 February 2014. The offering attracted strong interest among Swedish and international institutional investors as well as Swedish retail investors. The Offering was over-subscribed multiple times. The final offering price has been set at SEK 46 per share, corresponding to a market value of all shares issued by Bufab of MSEK 1,753.

Vinge’s team consisted of, among others, partners Charlotte Levin, Peter Bäärnhielm and Christina Kokko and associates Jonas Johansson, David Andersson, Mia Örnfeldt, Albert Wållgren and Rikard Lindahl.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024